Drug intelligence / Profile preview

68Ga-JJH0527

Development stage: Preclinical
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

68Ga-JJH0527 is a radiopharmaceutical agent labeled with gallium-68, designed for use in positron emission tomography (PET) imaging. It is an investigational compound and, based on its naming convention and context, likely targets a specific molecular marker or receptor for diagnostic imaging of certain cancers. However, no direct information about its precise target or clinical indication was found in the provided search results. The "JJH" code suggests it may be part of a series of novel PET tracers under preclinical or early clinical development.

Other names: 68Ga-JJH0527

Beyond the preview

Go deeper on 68Ga-JJH0527.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-JJH0527.

Explore the full profile